Zacks Research Weighs in on STERIS’s Q1 Earnings (NYSE:STE)

STERIS plc (NYSE:STE) – Zacks Research reduced their Q1 2026 earnings per share (EPS) estimates for STERIS in a note issued to investors on Wednesday, June 4th. Zacks Research analyst R. Department now forecasts that the medical equipment provider will post earnings per share of $2.29 for the quarter, down from their prior forecast of $2.31. The consensus estimate for STERIS’s current full-year earnings is $9.08 per share. Zacks Research also issued estimates for STERIS’s Q3 2026 earnings at $2.53 EPS, Q4 2026 earnings at $2.74 EPS, FY2026 earnings at $9.92 EPS, Q1 2027 earnings at $2.58 EPS, Q2 2027 earnings at $2.63 EPS, Q3 2027 earnings at $2.80 EPS, Q4 2027 earnings at $2.67 EPS and FY2027 earnings at $10.68 EPS.

A number of other research firms have also recently commented on STE. Stephens reissued an “overweight” rating and set a $250.00 price target on shares of STERIS in a report on Thursday, May 15th. Morgan Stanley raised their price objective on STERIS from $240.00 to $260.00 and gave the company an “equal weight” rating in a research report on Monday, May 19th. Citigroup restated an “outperform” rating on shares of STERIS in a research report on Friday, May 16th. Wall Street Zen lowered STERIS from a “strong-buy” rating to a “buy” rating in a research report on Friday, May 30th. Finally, JMP Securities raised their price objective on STERIS from $265.00 to $280.00 and gave the company a “market outperform” rating in a research report on Friday, May 16th. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $263.83.

STERIS Price Performance

NYSE:STE opened at $242.28 on Monday. The company has a quick ratio of 1.40, a current ratio of 2.13 and a debt-to-equity ratio of 0.32. The business’s 50-day simple moving average is $230.96 and its two-hundred day simple moving average is $222.21. The stock has a market cap of $23.83 billion, a PE ratio of 51.44 and a beta of 0.94. STERIS has a 52 week low of $200.98 and a 52 week high of $252.79.

STERIS (NYSE:STE) last posted its quarterly earnings results on Wednesday, May 14th. The medical equipment provider reported $2.74 EPS for the quarter, beating analysts’ consensus estimates of $2.59 by $0.15. The business had revenue of $1.48 billion for the quarter, compared to analysts’ expectations of $1.47 billion. STERIS had a return on equity of 13.91% and a net margin of 8.66%. The business’s quarterly revenue was up 5.7% on a year-over-year basis. During the same period last year, the firm earned $2.58 earnings per share.

Institutional Trading of STERIS

Institutional investors have recently added to or reduced their stakes in the company. Geneos Wealth Management Inc. lifted its stake in STERIS by 416.0% in the first quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 104 shares during the last quarter. Avalon Trust Co bought a new stake in STERIS in the fourth quarter worth about $30,000. Human Investing LLC bought a new stake in STERIS in the fourth quarter worth about $31,000. Grove Bank & Trust lifted its stake in STERIS by 4,733.3% in the first quarter. Grove Bank & Trust now owns 145 shares of the medical equipment provider’s stock worth $33,000 after purchasing an additional 142 shares during the last quarter. Finally, Anfield Capital Management LLC lifted its stake in STERIS by 100.0% in the fourth quarter. Anfield Capital Management LLC now owns 182 shares of the medical equipment provider’s stock worth $37,000 after purchasing an additional 91 shares during the last quarter. Institutional investors own 94.69% of the company’s stock.

Insider Buying and Selling

In related news, SVP Cary L. Majors sold 12,828 shares of STERIS stock in a transaction dated Tuesday, May 20th. The stock was sold at an average price of $250.08, for a total value of $3,208,026.24. Following the completion of the transaction, the senior vice president now owns 11,372 shares in the company, valued at approximately $2,843,909.76. This trade represents a 53.01% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Daniel A. Carestio sold 17,626 shares of the firm’s stock in a transaction dated Thursday, June 5th. The stock was sold at an average price of $242.56, for a total transaction of $4,275,362.56. Following the completion of the sale, the chief executive officer now directly owns 51,385 shares of the company’s stock, valued at approximately $12,463,945.60. The trade was a 25.54% decrease in their position. The disclosure for this sale can be found here. 1.14% of the stock is currently owned by company insiders.

STERIS Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 26th. Investors of record on Tuesday, June 10th will be given a $0.57 dividend. The ex-dividend date of this dividend is Tuesday, June 10th. This represents a $2.28 annualized dividend and a yield of 0.94%. STERIS’s dividend payout ratio is currently 36.77%.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.